Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor
Journal of Medicinal Chemistry · 23.01.2025 · 68 (2) · 1924-1939
DOI: 10.1021/acs.jmedchem.4c02662 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 08.01.2025. Verfasst von Qinda Ye und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Discovery Chemistry, Incyte Research Institute, Incyte Corporation, Wilmington, Delaware 19803 United States. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Incyte.
Abstract (Originalsprache)
The inhibition of mutant KRAS proteins has emerged as a promising approach for treating KRAS-driven cancers, as evidenced by the clinical success of KRAS G12C inhibitors. KRAS G12D, the most common mutant, promises significant expansion of the addressable patient population; however, the reduced nucleophilicity of aspartate compared to cysteine poses significant challenges in balancing sufficient potency with ADME properties to support oral exposure. Herein, we describe the discovery of KRAS G12D inhibitor 23 (INCB159020), which achieves oral exposure in nonhuman primate (NHP). Starting from a weakly potent hit, structure-based drug design was utilized to drive significant potency. Focus on molecular rigidity and balanced polarity then allowed for successful optimization of properties required for oral exposure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Discovery Chemistry, Incyte Research Institute, Incyte Corporation, Wilmington, Delaware 19803 United States.
- Department of Computational Chemistry, Incyte Research Institute, Incyte Corporation, Wilmington, Delaware 19803, United States.
- Department of Applied Technology, Incyte Research Institute, Incyte Corporation, Wilmington, Delaware 19803, United States.
- Department of Preclinical Pharmacology, Incyte Research Institute, Incyte Corporation, Wilmington, Delaware 19803, United States.
- Department of DMB, Incyte Research Institute, Incyte Corporation, Wilmington, Delaware 19803, United States.
ORCID-Profile: Alexander Sokolsky
Förderung
- Incyte
Zitieren
APA
Ye, Q., Shvartsbart, A., Li, Z., Gan, P., Policarpo, R. L., Qi, C., Roach, J. J., Zhu, W., McCammant, M. S., Hu, B., Li, G., Yin, H., Carlsen, P., Hoang, G., Zhao, L., Susick, R., Zhang, F., Lai, C. T., Allali Hassani, A., …, & Wang, X. (2025). Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor. Journal of Medicinal Chemistry, 68(2), 1924-1939. https://doi.org/10.1021/acs.jmedchem.4c02662
Vancouver
Ye Q, Shvartsbart A, Li Z, Gan P, Policarpo RL, Qi C, et al. Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor. Journal of Medicinal Chemistry. 2025;68(2):1924-1939. doi:10.1021/acs.jmedchem.4c02662
BibTeX
@article{Ye2025,
author = {Ye, Qinda and Shvartsbart, Artem and Li, Zhenwu and Gan, Pei and Policarpo, Rocco L and Qi, Chao and Roach, Jeremy J and Zhu, Wenyu and McCammant, Matthew S and Hu, Bin and Li, Gencheng and Yin, Haolin and Carlsen, Peter and Hoang, Gia and Zhao, Le and Susick, Robert and Zhang, Fenglei and Lai, Cheng-Tsung and Allali Hassani, Abdellah and Epling, Leslie B and Gallion, Alexandra and Kurzeja-Lipinski, Kerri and Gallagher, Karen and Roman, Valerie and Farren, Matthew R and Kong, Weixi and Deller, Marc C and Zhang, Guofeng and Covington, Maryanne and Diamond, Sharon and Kim, Sunkyu and Yao, Wenqing and Sokolsky, Alexander and Wang, Xiaozhao},
title = {Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {2},
pages = {1924--1939},
doi = {10.1021/acs.jmedchem.4c02662}
}
EUVIMED